Rao, Arjun
University of California, San Francisco
5 papers on CoChatORCID 0000-0003-4480-3190
Most cited papers
- Verified
Toil enables reproducible, open source, big biomedical data analyses
Vivian, J., Rao, A. A., Nothaft, F. A., Ketchum, C., Armstrong, J., Novak, A., Pfeil, J., Narkizian, J., Deran, A. D., Musselman-Brown, A., et al. (2017) · Nature Biotechnology
Scientific Computing and Data ManagementGenomics and Phylogenetic Studies
Cited by 1,365
- Verified
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., Lerario, A. M., Else, T., Knijnenburg, T. A., Ciriello, G., et al. (2016) · Cancer Cell
Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer
Cited by 657
- Verified
Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell
vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers
Cited by 538
- Verified
Comprehensive pan-genomic characterization of adrenocortical carcinoma
Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., Lerario, A. M., Else, T., Knijnenburg, T. A., Ciriello, G., et al. (2016) · Cancer Cell
Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer
Cited by 165
- Verified
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
Wang, V. E., Blaser, B. W., Patel, R. K., Behbehani, G. K., Rao, A. A., Durbin-Johnson, B., Jiang, T., Logan, A. C., Settles, M., Mannis, G. N., et al. (2021) · Blood Cancer Discovery
Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes
Cited by 11
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free